ACAD

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 8

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.1401 to $41.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 14

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,598

Underlying: Common Stock · 1,972 shares

Expires 2028-04-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 13

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,594

Underlying: Common Stock · 4,593 shares

Expires 2027-09-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 12

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,911

Underlying: Common Stock · 4,439 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 11

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 552

Underlying: Common Stock · 6,063 shares

Expires 2026-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 10

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,900 shares

Expires 2025-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-19-049231 · doc4.xml · derivative · entry 9

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2024-05-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 7

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,645

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.49 to $39.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 6

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 5

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 4

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 3

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 2

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-049231 · doc4.xml · nonDerivative · entry 1

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 860 shares of the Issuer's common stock acquired by the reporting person on November 15, 2018 and 573 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 pursuant to an employee stock purchase program.

SEC source: 0001209191-19-049230 · doc4.xml · derivative · entry 4

Daly James M · CIK 0001560782 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2028-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-19-049230 · doc4.xml · nonDerivative · entry 3

Daly James M · CIK 0001560782 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001209191-19-049230 · doc4.xml · nonDerivative · entry 2

Daly James M · CIK 0001560782 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.33 to $38.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-19-049230 · doc4.xml · nonDerivative · entry 1

Daly James M · CIK 0001560782 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001638599-19-000636 · doc4_6166.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-06-25

F1 · derivative.exercise_date: 15,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of ACADIA Pharmaceuticals Inc. (the "Issuer") were granted under the Issuer's 2010 Equity Incentive Plan to each of Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in their capacity as directors of the Issuer. The Stock Options with a strike price of $25.24 vest in 4 equal quarterly installments beginning on June 26, 2019 and expire on June 25, 2029. Julian C. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F1 · ownership.nature: 15,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of ACADIA Pharmaceuticals Inc. (the "Issuer") were granted under the Issuer's 2010 Equity Incentive Plan to each of Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in their capacity as directors of the Issuer. The Stock Options with a strike price of $25.24 vest in 4 equal quarterly installments beginning on June 26, 2019 and expire on June 25, 2029. Julian C. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F2 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Biggar do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. The Adviser has investment and dispositive power over the Stock Options and any common stock of the Issuer received as a result of the exercise of stock options.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-19-039525 · doc4.xml · derivative · entry 1

SOLAND DANIEL B · CIK 0001318485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2029-06-26

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.

SEC source: 0001209191-19-039524 · doc4.xml · derivative · entry 1

Daly James M · CIK 0001560782 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2029-06-26

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.

SEC source: 0001209191-19-039523 · doc4.xml · derivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2029-06-26

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.

SEC source: 0001209191-19-039522 · doc4.xml · derivative · entry 1

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-26

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.

SEC source: 0001638599-19-000599 · doc4_6146.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,876

F2 · kind: Represents shares of Common Stock distributed by 667, L.P. ("667", and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F2 · price: Represents shares of Common Stock distributed by 667, L.P. ("667", and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F5 · balance_after: Common Stock held directly by Julian C. Baker including 31,229 shares of Common Stock received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-19-000599 · doc4_6146.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,876

F2 · kind: Represents shares of Common Stock distributed by 667, L.P. ("667", and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F2 · price: Represents shares of Common Stock distributed by 667, L.P. ("667", and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F4 · balance_after: Common Stock held directly by Felix J. Baker including 31,229 shares of Common Stock received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-19-000599 · doc4_6146.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,315,146

F2 · kind: Represents shares of Common Stock distributed by 667, L.P. ("667", and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F2 · price: Represents shares of Common Stock distributed by 667, L.P. ("667", and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-19-026848 · doc4.xml · derivative · entry 2

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,442

Underlying: Common Stock · 3,442 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

SEC source: 0001209191-19-026848 · doc4.xml · derivative · entry 1

Miller Eric Alejandro · CIK 0001758494 · Controller & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,039

Underlying: Common Stock · 6,039 shares

Expires 2029-04-29

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-026847 · doc4.xml · derivative · entry 2

YANG MICHAEL J. · CIK 0001702283 · EVP and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,827

Underlying: Common Stock · 16,827 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

SEC source: 0001209191-19-026847 · doc4.xml · derivative · entry 1

YANG MICHAEL J. · CIK 0001702283 · EVP and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,042

Underlying: Common Stock · 59,042 shares

Expires 2029-04-29

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-026846 · doc4.xml · derivative · entry 2

Ridloff Elena · CIK 0001772518 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,981

Underlying: Common Stock · 12,981 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

SEC source: 0001209191-19-026846 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,547

Underlying: Common Stock · 45,547 shares

Expires 2029-04-29

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-026845 · doc4.xml · derivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,019

Underlying: Common Stock · 12,019 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

SEC source: 0001209191-19-026845 · doc4.xml · derivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,173

Underlying: Common Stock · 42,173 shares

Expires 2029-04-29

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-026844 · doc4.xml · derivative · entry 2

Stankovic Srdjan R. · CIK 0001432545 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,462

Underlying: Common Stock · 38,462 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

SEC source: 0001209191-19-026844 · doc4.xml · derivative · entry 1

Stankovic Srdjan R. · CIK 0001432545 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,953

Underlying: Common Stock · 134,953 shares

Expires 2029-04-29

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-026842 · doc4.xml · derivative · entry 2

DAVIS STEPHEN · CIK 0001131146 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

SEC source: 0001209191-19-026842 · doc4.xml · derivative · entry 1

DAVIS STEPHEN · CIK 0001131146 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,298

Underlying: Common Stock · 219,298 shares

Expires 2029-04-29

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

SEC source: 0001209191-19-022500 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F2 · derivative.exercise_date: 75% of the shares subject to the Restricted Stock Units shall vest on the third anniversary of the grant date, and the remaining 25% shall vest on the fourth anniversary of the grant date.

F2 · derivative.expiration_date: 75% of the shares subject to the Restricted Stock Units shall vest on the third anniversary of the grant date, and the remaining 25% shall vest on the fourth anniversary of the grant date.

SEC source: 0001209191-19-003427 · doc4.xml · derivative · entry 3

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2019-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-19-003427 · doc4.xml · nonDerivative · entry 2

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-19-003427 · doc4.xml · nonDerivative · entry 1

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001638599-18-001307 · doc4_5797.xml · derivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,569

Underlying: Common Stock · 1,569 shares

Expires 2019-12-17

F11 · price: Pursuant to Instruction 4(c)(iii), this response has been left blank.

F14 · balance_after: Reflects 1,569 warrants to purchase Common Stock at an exercise price of $0.01 per share with an expiration date of December 17, 2019 held directly by Felix J. Baker received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-18-001307 · doc4_5797.xml · derivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,569

Underlying: Common Stock · 1,569 shares

Expires 2019-12-17

F11 · price: Pursuant to Instruction 4(c)(iii), this response has been left blank.

F13 · balance_after: Reflects 1,569 warrants to purchase Common Stock at an exercise price of $0.01 per share with an expiration date of December 17, 2019 held directly by Julian C. Baker received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-18-001307 · doc4_5797.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 10,731 shares

Expires 2019-12-17

F11 · price: Pursuant to Instruction 4(c)(iii), this response has been left blank.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: Represents 10,731 warrants to purchase Common Stock at an exercise price of $0.01 per share with an expiration date of December 17, 2019 distributed by 14159, L.P. as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 14159, L.P.

F12 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's securities reported in column 9 of Table II directly held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

SEC source: 0001638599-18-001307 · doc4_5797.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,647

F7 · balance_after: Reflects 71,647 shares of Common Stock held directly by Felix J. Baker received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-18-001307 · doc4_5797.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,647

F6 · balance_after: Reflects 71,647 shares of Common Stock held directly by Julian C. Baker received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-18-001307 · doc4_5797.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

F4 · ownership.nature: Represents 489,977 shares of Common Stock distributed by 14159, L.P. ("14159", and together with 667 and Life Sciences (the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 14159, L.P.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Common Stock reported in column 5 of Table I directly held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-18-001307 · doc4_5797.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 35,976,940

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences") purchased 585,882 and 11,178,823 shares of Common Stock, respectively, for $17.00 per share in an underwritten public offering (the "Offering") that closed on November 30, 2018.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-18-001307 · doc4_5797.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,736,902

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences") purchased 585,882 and 11,178,823 shares of Common Stock, respectively, for $17.00 per share in an underwritten public offering (the "Offering") that closed on November 30, 2018.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.